Citryll Unveils Promising Findings for CIT-013 in Rheumatoid Arthritis
Citryll, an innovative biotech company specializing in treatments for immune-mediated inflammatory diseases, has recently presented exciting findings from its Phase I clinical trial of CIT-013, a novel therapy targeting Extracellular Traps (ETs) in rheumatoid arthritis (RA) patients. During the American College of Rheumatology (ACR) Convergence, held in Chicago, the company shared compelling data suggesting that CIT-013 has a favorable safety profile and shows potential for meaningful clinical effectiveness.
Overview of Phase I Clinical Trial Results
The recently presented data highlighted that CIT-013 exhibited a high tolerability rate among participants, with no serious treatment-related side effects reported. This is significant as it lays the groundwork for the advancement of CIT-013 into Phase IIa studies.
A notable outcome from the trial was the evidence of clinically relevant reductions in disease activity among the RA participants treated with CIT-013. This finding not only speaks to the drug's effectiveness but also emphasizes the potential it holds for improving the lives of those affected by this debilitating condition.
Supportive Data from Preclinical Studies
In addition to the Phase I trial results, Citryll showcased two supplementary posters detailing preclinical study outcomes. The first poster discussed the use of radiolabeled CIT-013 as a diagnostic imaging tool, demonstrating its ability to accumulate specifically in inflamed tissues. This characteristic could enhance the monitoring of treatment responses in RA and potentially in other inflammatory diseases.
The second poster focused on calprotectin, a biomarker of disease activity. Research revealed a correlation between calprotectin serum levels and treatment responses, further endorsing its role as a reliable biomarker for RA management.
Expert Insights from Citryll's Leadership
Maarten Kraan, the Chief Medical Officer at Citryll, expressed enthusiasm regarding the trial's findings. He stated, "The comprehensive dataset illustrates the unique potential of CIT-013 as a first-in-class therapy aimed at ETs for treating RA and related inflammatory diseases. We're excited about the positive safety profile and preliminary efficacy signals from our Phase I study, which affirm our decision to transition CIT-013 to Phase IIa studies. This body of translational evidence reinforces our commitment to exploring ET inhibition as a viable option for autoimmune conditions, heightening our confidence in the ongoing clinical development.”
Citryll is currently in the process of conducting a Phase IIa study named Citydream, focusing on RA. Another Phase IIa trial targeting hidradenitis suppurativa is anticipated to begin shortly, highlighting Citryll's expanding research agenda.
Details of the Presented Posters
During the ACR conference, Citryll showcased the following poster details:
Poster 1: Phase I Trial in Participants with Rheumatoid Arthritis and Healthy Volunteers
Date: 26 October 2025
Session: Rheumatoid Arthritis – Treatment Poster I
Abstract Number: 0493
Poster 2: Calprotectin Serum Levels as a Biomarker
Date: 26 October 2025
Session: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I
Abstract Number: 0431
Poster 3: Radiolabeled CIT-013 for Visualizing Inflamed Joints
Date: 27 October 2025
Session: Innate Immunity Poster
Abstract Number: 0928
About CIT-013 and Citryll
CIT-013 is Citryll’s pioneering monoclonal antibody targeting Extracellular Traps (ETs) that contribute significantly to inflammation in RA and other immune-mediated diseases. It features a unique dual mechanism of action that enhances the clearance of existing ETs while preventing the formation of new traps. This specificity minimizes off-target effects and represents a substantial advancement in therapeutic strategies traditionally focused on symptom management.
Citryll is dedicated to creating innovative solutions for treating inflammatory diseases, with the potential of CIT-013 paving the way for new therapeutic classes that address the underlying inflammatory processes.
In conclusion, CIT-013 not only promises to enhance treatment protocols for RA but also seeks to offer comprehensive care options for conditions where current treatments often fall short.
Contacts
Citryll
Sjoerd van Gorp, COO / CFO
Email: info@citryll.com
Citryll Media Contacts
ICR Healthcare
Amber Fennell, Stephanie Cuthbert, Lucy Featherstone
Email: citryll@icrinc.com
Frequently Asked Questions
What were the main findings from the Phase I study of CIT-013?
The Phase I study revealed that CIT-013 was well tolerated, with no serious adverse effects, and showed clinically meaningful reductions in disease activity among RA patients.
What is the significance of the preclinical studies presented?
Preclinical studies supported the clinical program by demonstrating CIT-013's targeted accumulation in inflamed tissues and its correlation with a potential biomarker, calprotectin.
What does Citryll aim to achieve with CIT-013?
Citryll aims to develop CIT-013 as a first-in-class therapy that effectively targets ETs, addressing the underlying causes of inflammation in autoimmune diseases.
Are there plans for further studies involving CIT-013?
Yes, Citryll has initiated a Phase IIa study known as Citydream in RA, with plans for another trial in hidradenitis suppurativa.
How can I contact Citryll for more information?
For inquiries, you can contact Sjoerd van Gorp via email at info@citryll.com.
